Ideaya Biosciences Inc

+0.11 (+0.92%)
Earnings Announcements

Ideaya Achieves First Milestone In Ongoing Collaboration With Gsk

Published: 08/29/2022 10:13 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Announces Achievement of First Milestone in Ongoing Collaboration With Gsk for Potential First-in-class Pol Theta Helicase Inhibitor Development Candidate.
Ideaya Biosciences Inc- Potential to Realize Preclinical and Clinical Milestones Up to $20 Million Total for Preclinical to Early Phase 1 Clinical.
Ideaya Biosciences Inc- Targeting First-in-human Clinical Evaluation of Pol Theta Helicase Inhibitor Dc in Combination With Niraparib in H1 2023.
Revenue is expected to be $6.64 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $6.64 Million
Next Quarter EPS Guidance is expected to be -$0.68

More details on our Analysts Page.